

P7700 Cited References

Roar PLTP Activity Assay Kit

1. Deckert V, Lemaire S, Ripoll PJ, et al. Recombinant human plasma phospholipid transfer protein (PLTP) to prevent bacterial growth and to treat sepsis. *Sci Rep.* **2017**;7(1):3053-017-03285-9.
2. Kuwano T, Bi X, Cipollari E, et al. Overexpression and deletion of phospholipid transfer protein reduce HDL mass and cholesterol efflux capacity but not macrophage reverse cholesterol transport. *J Lipid Res.* **2017**;58(4):731-741.
3. Qin Y, Ran L, Wang J, et al. Capsaicin supplementation improved risk factors of coronary heart disease in individuals with low HDL-C levels. *Nutrients.* **2017**;9(9):1037.
4. Khetarpal SA, Schjoldager KT, Christoffersen C, et al. Loss of function of GALNT2 lowers high-density lipoproteins in humans, nonhuman primates, and rodents. *Cell Metabolism.* **2016**;24(2):234-245.
5. Gross JJ, Kessler EC, Albrecht C, Bruckmaier RM. Response of the cholesterol metabolism to a negative energy balance in dairy cows depends on the lactational stage. *PLoS one.* **2015**;10(6):e0121956.
6. Kim DS, Burt AA, Ranchalis JE, et al. Plasma phospholipid transfer protein (PLTP) activity inversely correlates with carotid artery disease: Effects of paraoxonase 1 enzyme activity and genetic variants on PLTP activity. *J Lipid Res.* **2015**;56:1351-1362.
7. Brehm A, Geraghty P, Campos M, et al. Cathepsin G degradation of phospholipid transfer protein (PLTP) augments pulmonary inflammation. *FASEB J.* **2014**;28(5):2318-2331.
8. Ghazalpour A, Bennett BJ, Shih D, et al. Genetic regulation of mouse liver metabolite levels. *Mol Syst Biol.* **2014**;10(5):730.
9. Gidwani S, Phelan N, McGill J, et al. Polycystic ovary syndrome influences the level of serum amyloid A and activity of phospholipid transfer protein in HDL(2) and HDL(3). *Hum Reprod.* **2014**;29(7):1518-1525.
10. Kessler E, Gross J, Bruckmaier R, Albrecht C. Cholesterol metabolism, transport, and hepatic regulation in dairy cows during transition and early lactation. *J Dairy Sci.* **2014**;97(9):5481-5490.
11. Yassine HN, Belopolskaya A, Schall C, Stump CS, Lau SS, Reaven PD. Enhanced cholesterol efflux to HDL through the ABCA1 transporter in hypertriglyceridemia of type 2 diabetes. *Metab Clin Exp.* **2014**;63(5):727-734.
12. Deckert V, Kretz B, Habbout A, et al. Development of abdominal aortic aneurysm is decreased in mice with plasma phospholipid transfer protein deficiency. *The American Journal of Pathology.* **2013**;183(3):975-986.
13. Robins SJ, Lyass A, Brocchia RW, Massaro JM, Vasan RS. Plasma lipid transfer proteins and cardiovascular disease: the framingham heart study. *Atherosclerosis.* **2013**;228(1):230-236.
14. Orsoni A, Villard EF, Bruckert E, et al. Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemia. *J Lipid Res.* **2012**;53(4):767-775. doi: 10.1194/jlr.M024141.
15. Bellanger N, Orsoni A, Julia Z, et al. Atheroprotective reverse cholesterol transport pathway is defective in familial hypercholesterolemia. *Arterioscler Thromb Vasc Biol.* **2011**;31(7):1675-1681. doi: 10.1161/ATVBAHA.111.227181.
16. Marchesi M, Parolini C, Caligari S, et al. Rosuvastatin does not affect human apolipoprotein A-I expression in genetically modified mice: A clue to the disputed effect of statins on HDL. *Br J Pharmacol.* **2011**;164(5):1460-1468.
17. Masson D, Deckert V, Gautier T, et al. Worsening of diet-induced atherosclerosis in a new model of transgenic rabbit expressing the human plasma phospholipid transfer protein. *Arterioscler Thromb Vasc Biol.* **2011**;31(4):766-774.
18. Wang D, Han J, Yu Y, et al. Chitosan oligosaccharide decreases very-low-density lipoprotein triglyceride and increases high-density lipoprotein cholesterol in high-fat-diet-fed rats. *Exp Biol Med.* **2011**;236(9):1064-1069.
19. Briand F, Treguier M, Andre A, et al. Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model. *J Lipid Res.* **2010**;51(4):763-770.
20. Gautier T, Paul C, Deckert V, et al. Innate immune response triggered by triacyl lipid A is dependent on phospholipid transfer protein (PLTP) gene expression. *FASEB J.* **2010**;24(9):3544-3554. doi: 10.1096/fj.09-152876.
21. Cavusoglu E, Marmur JD, Chhabra S, Chopra V, Eng C, Jiang XC. Relation of baseline plasma phospholipid transfer protein (PLTP) activity to left ventricular systolic dysfunction in patients referred for coronary angiography. *Atherosclerosis.* **2009**;207(1):261-265.
22. Henderson RJ, Leon CG, Wasan KM. Differences in human phospholipid transfer protein activity following incubation of fungizone® compared to lipid-based amphotericin-B formulations in normolipidemic and hyperlipidemic plasma. *Drug Dev Ind Pharm.* **2009**;35(9):1139-1146.
23. Henderson RJ, Wasan KM, Leon CG. Haptoglobin inhibits phospholipid transfer protein activity in hyperlipidemic human plasma. *Lipids in Health and Disease.* **2009**;8(1):27. doi: 10.1186/1476-511X-8-27.
24. Lakomy D, Rebe C, Sberna AL, et al. Liver X receptor-mediated induction of cholesteryl ester transfer protein expression is selectively impaired in inflammatory macrophages. *Arterioscler Thromb Vasc Biol.* **2009**;29(11):1923-1929. doi: 10.1161/ATVBAHA.109.193201.
25. Schlitt A, Blankenberg S, Bickel C, et al. PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: The AtheroGene study. *J Lipid Res ; J Lipid Res.* **2009**;50(4):723-729.
26. Gautier T, Klein A, Deckert V, et al. Effect of plasma phospholipid transfer protein deficiency on lethal endotoxemia in mice. *J Biol Chem.* **2008**;283(27):18702-18710.
27. Thornton SJ, Wong E, Lee SD, Wasan KM. Effect of dietary fat on hepatic liver X receptor expression in P-glycoprotein deficient mice: Implications for cholesterol metabolism. *Lipids in Health and Disease.* **2008**;7:21.
28. Liu R, Hojjati MR, Devlin CM, Hansen IH, Jiang XC. Macrophage phospholipid transfer protein deficiency and ApoE secretion: Impact on mouse plasma

- cholesterol levels and atherosclerosis. *Arterioscler Thromb Vasc Biol.* **2007**;27(1):190-196.
29. Schlitt A, Heine GH, Jiang XC, et al. Phospholipid transfer protein in hemodialysis patients. *Am J Nephrol.* **2007**;27(2):138-143.
 30. Briand F, Magot T, Krempf M, Nguyen P, Ouguerram K. Effects of atorvastatin on high-density lipoprotein apolipoprotein A-I metabolism in dogs. *Eur J Clin Invest.* **2006**;36(4):224-230.
 31. Klein A, Deckert V, Schneider M, et al. Alpha-tocopherol modulates phosphatidylserine externalization in erythrocytes: Relevance in phospholipid transfer protein-deficient mice. *Arterioscler Thromb Vasc Biol.* **2006**;26(9):2160-2167.
 32. Patankar N, Wasan KM. Role of phospholipid transfer protein on the plasma distribution of amphotericin B following the incubation of different amphotericin B formulations. *Pharm Res.* **2006**;23(5):1020-1024.
 33. Lee JY, Timmins JM, Mulya A, et al. HDLs in apoA-I transgenic Abca1 knockout mice are remodeled normally in plasma but are hypercatabolized by the kidney. *J Lipid Res.* **2005**;46(10):2233-2245.
 34. Roy S, Hyogo H, Yadav SK, et al. A biphasic response of hepatobiliary cholesterol metabolism to dietary fat at the onset of obesity in the mouse. *Hepatology.* **2005**;41(4):887-895.
 35. Timmins JM, Lee JY, Boudyguina E, et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. *J Clin Invest.* **2005**;115(5):1333-1342.
 36. Wu MK, Cohen DE. Phosphatidylcholine transfer protein regulates size and hepatic uptake of high-density lipoproteins. *Am J Physiol Gastrointest Liver Physiol.* **2005**;289(6):G1067-74.
 37. Beyer TP, Schmidt RJ, Foxworthy P, et al. Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-alpha agonist in mice: Effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo. *J Pharmacol Exp Ther.* **2004**;309(3):861-868.
 38. Schneider M, Verges B, Klein A, et al. Alterations in plasma vitamin E distribution in type 2 diabetic patients with elevated plasma phospholipid transfer protein activity. *Diabetes.* **2004**;53(10):2633-2639.
 39. Desrumaux CM, Mak PA, Boisvert WA, et al. Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells. *J Lipid Res.* **2003**;44(8):1453-1461.
 40. Hudgins LC, Parker TS, Levine DM, et al. A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers. *J Lipid Res.* **2003**;44(8):1489-1498.
 41. Laffitte BA, Joseph SB, Chen M, et al. The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. *Mol Cell Biol.* **2003**;23(6):2182-2191.
 42. Masson D, Drouineaud V, Moiroux P, et al. Human seminal plasma displays significant phospholipid transfer activity due to the presence of active phospholipid transfer protein. *Mol Hum Reprod.* **2003**;9(8):457-464.
 43. Schlitt A, Bickel C, Thumma P, et al. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. *Arterioscler Thromb Vasc Biol.* **2003**;23(10):1857-1862.
 44. Yang XP, Yan D, Qiao C, et al. Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. *Arterioscler Thromb Vasc Biol.* **2003**;23(9):1601-1607.
 45. Cao G, Beyer TP, Yang XP, et al. Phospholipid transfer protein is regulated by liver X receptors in vivo. *J Biol Chem.* **2002**;277(42):39561-39565.